v3.26.1
Collaborations and Other Arrangements (Details)
$ in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 23, 2021
USD ($)
Jan. 31, 2025
USD ($)
Mar. 31, 2026
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2024
CAD ($)
Dec. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Junshi Biosciences                
Collaborative Arrangements And Noncollaborative Arrangement Transactions                
Royalties due     $ 2.4       $ 4.7  
Milestone payments, amount   $ 12.5   $ 12.5        
Junshi Biosciences | Intangible assets, net and accrued and other current liabilities                
Collaborative Arrangements And Noncollaborative Arrangement Transactions                
Accrued milestone payment               $ 25.0
Canada license agreement with Apotex                
Collaborative Arrangements And Noncollaborative Arrangement Transactions                
Company an upfront payment received         $ 6.3      
Regulatory and sales milestones eligible to receive           $ 51.5    
Collaboration agreement, royalty on net sales, percentage         20.00% 20.00%    
Renewal term     10 years          
Vaccinex License Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions                
Accrued milestone payment             $ 1.0  
Maximum aggregate milestone payments to be made $ 2.0              
Maximum aggregate amount payable for achievement of certain clinical milestones low single digit royalties on global net sales of any approved licensed products $ 11.5              
Clinical milestone payments     $ 1.0